Arimoclomol: a potential therapy under development for ALS.

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease.
• Arimoclomol enhances heat shock protein expression, aiding cellular stress response.
• Current ALS treatments are limited, necessitating novel therapeutic approaches.

Purpose of the Study:

• To review the rationale for investigating arimoclomol in ALS.
• To synthesize available safety and pharmacokinetic data for arimoclomol.
• To evaluate arimoclomol's potential as an ALS therapeutic.

Main Methods:

• Review of published and unpublished literature on arimoclomol over two decades.
• Analysis of preclinical data in motor neuron disease models.
• Examination of safety and pharmacokinetic data from human studies (Phase IIa).

Main Results:

• Arimoclomol improved survival and muscle function in an ALS mouse model.
• Phase IIa studies demonstrated safety in ALS patients up to 300 mg/day.
• Ongoing studies are investigating arimoclomol in familial ALS linked to SOD1 mutations.

Conclusions:

• Arimoclomol's pharmacological profile and preclinical data support its therapeutic potential in ALS.
• Further investigation in sporadic and familial ALS is warranted based on existing evidence.
• Arimoclomol represents a promising therapeutic candidate for ALS management.